CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil.

Trial Profile

CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs Latrepirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms CONCERT
  • Sponsors Medivation
  • Most Recent Events

    • 10 Mar 2012 This trial has been completed in Germany, France, Sweden and Italy as reported by European Clinical Trials Database (Parent trial: EudraCT2008-008005-21).
    • 17 Jan 2012 Results published in a Medivation and Pfizer media release.
    • 17 Jan 2012 The open label extension study in Alzheimer's disease will be terminated, according to a media release from Medivation and Pfizer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top